Niagen Bioscience Inc (NAGE) financial statements and ratios from SEC XBRL: revenue $129.42M (TTM), net margin 13.4%, revenue growth -4.3% YoY, P/E 16.0. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $129.42M |
| Net Margin | 13.4% |
| Revenue Growth (YoY) | -4.3% |
| EPS Growth (YoY) | -80.0% |
| P/E Ratio | 16.0 |
| EV / EBITDA | 17.0 |
| Price / Book | 3.10 |
| Price / Sales | 1.98 |
| DCF Value (model) | $8.18 |
| DCF Upside vs Price | 154.8% |
| Altman Z-Score | 5.59 (safe) |
| Sector P/E (Healthcare) | 21.7 |
NAGE overview · NAGE earnings · NAGE KPIs · NAGE investor relations · NAGE ownership · NAGE peers · NAGE filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.